HUTCHMED (China) (HMDCF) Change in Receivables (2020 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Change in Receivables came in at -$6.5 million in Q1 2021, down 480.47% year-over-year from $1.7 million in Q1 2020, and down 480.47% quarter-over-quarter from $1.7 million in Q1 2020.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Change in Receivables (2020 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Change in Receivables for 2 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |